Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
暂无分享,去创建一个
[1] G. Golm,et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.
[2] P. Kushner,et al. Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors , 2010, Postgraduate medicine.
[3] M. Davies,et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study , 2010, International journal of clinical practice.
[4] A. Scheen,et al. [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. , 2010, Revue medicale de Liege.
[5] S. Garg. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. , 2010, Diabetes technology & therapeutics.
[6] V. Mohan,et al. Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario , 2010, Journal of diabetes science and technology.
[7] V. Basevi. Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.
[8] A. Peters,et al. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk , 2009, Cleveland Clinic Journal of Medicine.
[9] R. Henry,et al. Pharmacotherapy of hyperglycemia , 2009, Expert opinion on pharmacotherapy.
[10] Bryan R Luce,et al. Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.
[11] D. Riche,et al. Impact of Sitagliptin on Markers of &bgr;-cell Function: A Meta-Analysis , 2009, The American journal of the medical sciences.
[12] Ambady Ramachandran,et al. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2) , 2009, Diabetologia.
[13] Melanie J. Davies,et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study , 2009, Current medical research and opinion.
[14] V. Mohan,et al. Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47) , 2009, European Journal of Clinical Nutrition.
[15] M. Davies,et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes * , 2008, Diabetes, obesity & metabolism.
[16] E. Liberopoulos,et al. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes , 2008, Expert opinion on pharmacotherapy.
[17] P. Stein,et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.
[18] F. Pi‐Sunyer,et al. The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight , 2008, Postgraduate medicine.
[19] K. Hermansen,et al. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.
[20] S. Yusuf,et al. The DREAM trial – Authors' reply , 2006, The Lancet.
[21] P. Stein,et al. Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes , 2006, International journal of clinical practice.
[22] Ronald Brazg,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.
[23] C. Snehalatha,et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.
[24] R. Glasgow,et al. A practical randomized trial to improve diabetes care , 2004, Journal of General Internal Medicine.
[25] Ambady Ramachandran,et al. Low risk threshold for acquired diabetogenic factors in Asian Indians. , 2004, Diabetes research and clinical practice.
[26] M. Riddle,et al. Timely initiation of basal insulin. , 2004, The American journal of medicine.
[27] P. Cryer,et al. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.
[28] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.
[29] M. Engelgau,et al. Translation research for chronic disease: the case of diabetes. , 2000, Diabetes care.
[30] O. Pedersen,et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.
[31] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[32] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[33] V. Mohan,et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. , 2009, Diabetes research and clinical practice.